Metformin transporter pharmacogenomics: insights into drug disposition—where are we now?

Paul Chan, Li Shao, Brian Tomlinson, Yuzhen Zhang, Zhong Min Liu

研究成果: 雜誌貢獻回顧型文獻同行評審

3 引文 斯高帕斯(Scopus)

摘要

Introduction: Metformin is recommended as first-line treatment for type 2 diabetes (T2D) by all major diabetes guidelines. With appropriate usage it is safe and effective overall, but its efficacy and tolerability show considerable variation between individuals. It is a substrate for several drug transporters and polymorphisms in these transporter genes have shown effects on metformin pharmacokinetics and pharmacodynamics. Areas covered: This article provides a review of the current status of the influence of transporter pharmacogenomics on metformin efficacy and tolerability. The transporter variants identified to have an important influence on the absorption, distribution, and elimination of metformin, particularly those in organic cation transporter 1 (OCT1, gene SLC22A1), are reviewed. Expert opinion: Candidate gene studies have shown that genetic variations in SLC22A1 and other drug transporters influence the pharmacokinetics, glycemic responses, and gastrointestinal intolerance to metformin, although results are somewhat discordant. Conversely, genome-wide association studies of metformin response have identified signals in the pharmacodynamic pathways rather than the transporters involved in metformin disposition. Currently, pharmacogenomic testing to predict metformin response and tolerability may not have a clinical role, but with additional data from larger studies and availability of safe and effective alternative antidiabetic agents, this is likely to change.
原文英語
頁(從 - 到)1149-1159
頁數11
期刊Expert Opinion on Drug Metabolism and Toxicology
14
發行號11
DOIs
出版狀態已發佈 - 十一月 2 2018

ASJC Scopus subject areas

  • Toxicology
  • Pharmacology

指紋 深入研究「Metformin transporter pharmacogenomics: insights into drug disposition—where are we now?」主題。共同形成了獨特的指紋。

引用此